In prostate tumors, CD133 expression, another CSC marker, was not correlated to its promoter methylation status, whereas in colon cancer, the CD133 negative cells were shown to form tumors much more aggressive than their CD133 positive counterparts [14], [15]. This evidence concerns the gene PROM1 and colonic neoplasm.